相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial
Carolina Porras et al.
VACCINE (2022)
Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
David A. Spencer et al.
NATURE COMMUNICATIONS (2022)
The C5a-C5aR1 complement axis is essential for neutrophil recruitment to draining lymph nodes via high endothelial venules in cutaneous leishmaniasis
Borja Prat-Luri et al.
CELL REPORTS (2022)
Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells
Robert Hullsiek et al.
FRONTIERS IN IMMUNOLOGY (2022)
Complement C5a induces the generation of neutrophil extracellular traps by inhibiting mitochondrial STAT3 to promote the development of arterial thrombosis
Yejia Chen et al.
THROMBOSIS JOURNAL (2022)
One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study
Louise Baandrup et al.
CLINICAL INFECTIOUS DISEASES (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler et al.
CELL (2021)
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials
Filipe Colaro Mariz et al.
LANCET INFECTIOUS DISEASES (2021)
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
Partha Basu et al.
LANCET ONCOLOGY (2021)
A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial
Kathy J. Baisley et al.
CONTEMPORARY CLINICAL TRIALS (2021)
A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus
Bronwyn M. Gunn et al.
IMMUNITY (2021)
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine A Phase 3 Randomized Clinical Trial
Timo Vesikari et al.
JAMA NETWORK OPEN (2021)
Systems serology detects functionally distinct coronavirus antibody features in children and elderly
Kevin J. Selva et al.
NATURE COMMUNICATIONS (2021)
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Rachel Yamin et al.
NATURE (2021)
Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects
Michelle Meyer et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria
Elizabeth H. Aitken et al.
ELIFE (2021)
Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells
Kashyap R. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Human Papillomavirus Vaccination After COVID-19
Zheng Quan Toh et al.
JNCI CANCER SPECTRUM (2021)
A guide to vaccinology: from basic principles to new developments
Andrew J. Pollard et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response
Chun-Lan Zhuang et al.
EMERGING MICROBES & INFECTIONS (2021)
Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial
Sabrina H. Tsang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy
Francesco Nicoli et al.
VACCINES (2020)
Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth
Sarah Davidson et al.
CELL REPORTS (2020)
IgG-aggregates rapidly upregulate FcgRI expression at the surface of human neutrophils in a FcgRII-dependent fashion: A crucial role for FcgRI in the generation of reactive oxygen species
Sandrine Huot et al.
FASEB JOURNAL (2020)
A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
Tsetsegsaihan Batmunkh et al.
VACCINE (2020)
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
Susanne K. Kjaer et al.
ECLINICALMEDICINE (2020)
Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates
Charlotte Viant et al.
CELL (2020)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Melanie Drolet et al.
LANCET (2019)
A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
Tino F. Schwarz et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls
Hella Pasmans et al.
VACCINE (2019)
Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules
Zheng Quan Toh et al.
VACCINES (2019)
FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils
Louise W. Treffers et al.
FRONTIERS IN IMMUNOLOGY (2019)
Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis
Julia M. L. Brotherton et al.
PAPILLOMAVIRUS RESEARCH (2019)
Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection
Xinlin Liu et al.
EMERGING MICROBES & INFECTIONS (2019)
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
Elisabeth A. van Erp et al.
FRONTIERS IN IMMUNOLOGY (2019)
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
Bingyu Li et al.
ONCOIMMUNOLOGY (2018)
Extracellular Conformational Changes in the Capsid of Human Papillomaviruses Contribute to Asynchronous Uptake into Host Cells
Miriam Becker et al.
JOURNAL OF VIROLOGY (2018)
Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus
Joshua W. Wang et al.
JOURNAL OF VIROLOGY (2018)
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
Rengaswamy Sankaranarayanan et al.
VACCINE (2018)
Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development
Ligia A. Pinto et al.
VACCINE (2018)
Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults
Donald Brandon et al.
VACCINE (2018)
The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells
Hong-Sheng Dai et al.
IMMUNITY (2017)
Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells
Nike J. Kraeutler et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults
Fernanda Ana-Sosa-Batiz et al.
VACCINE (2017)
IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions
Chang-Han Lee et al.
NATURE IMMUNOLOGY (2017)
Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
Allan Hildesheim et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2016)
Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids
A. Handisurya et al.
BRITISH JOURNAL OF CANCER (2016)
Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen
Guanbo Wang et al.
MOLECULAR CELL (2016)
Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus
Ayan Dey et al.
PLOS ONE (2016)
Early Defensive Mechanisms against Human Papillomavirus Infection
Andrea Moerman-Herzog et al.
CLINICAL AND VACCINE IMMUNOLOGY (2015)
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2015)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Circulating CXCR5+CD4+ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines
Ken Matsui et al.
PLOS ONE (2015)
Alpha-Defensin HD5 Inhibits Furin Cleavage of Human Papillomavirus 16 L2 To Block Infection
Mayim E. Wiens et al.
JOURNAL OF VIROLOGY (2015)
Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer
Inge Langers et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells
Johan M. J. Van den Bergh et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial
Shuying S. Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Altered α-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment
Pascale Hubert et al.
JOURNAL OF PATHOLOGY (2014)
The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy
David A. Mancardi et al.
BLOOD (2013)
Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial
Simon R. M. Dobson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
Understanding and learning from the success of prophylactic human papillomavirus vaccines
John T. Schiller et al.
NATURE REVIEWS MICROBIOLOGY (2012)
Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion
Virginie M. Renoux et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Patricia M. Day et al.
CELL HOST & MICROBE (2010)
Sustained efficacy and immunogenicity of the HPV-16/18 ASO4-adjuvanted vaccine up to 7.3 years in young adult women
N. De Carvalho et al.
VACCINE (2010)
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway
Jose Yuste et al.
INFECTION AND IMMUNITY (2008)
Functional expression of IgA receptor FcαRI on human platelets
Kun Qian et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions
Judith F. Smith et al.
HUMAN VACCINES (2007)
Human α-defensins block papillomavirus infection
CB Buck et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88
RC Yang et al.
JOURNAL OF IMMUNOLOGY (2005)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-κB-mediated signalling, moderated by TGF-β
MY Yan et al.
IMMUNOLOGY AND CELL BIOLOGY (2005)
Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons
R Gutzmer et al.
IMMUNOLOGY (2004)
Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica
RP Viscidi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2004)
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
CD Harro et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
分享论文
